152 related articles for article (PubMed ID: 19542881)
21. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy strategies for hemophilia: benefits versus risks.
Petrus I; Chuah M; VandenDriessche T
J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
[TBL] [Abstract][Full Text] [Related]
23. Gut epithelial cells as targets for gene therapy of hemophilia.
Lozier JN; Yankaskas JR; Ramsey WJ; Chen L; Berschneider H; Morgan RA
Hum Gene Ther; 1997 Aug; 8(12):1481-90. PubMed ID: 9287148
[TBL] [Abstract][Full Text] [Related]
24. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
[TBL] [Abstract][Full Text] [Related]
25. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.
Lin Y; Chang L; Solovey A; Healey JF; Lollar P; Hebbel RP
Blood; 2002 Jan; 99(2):457-62. PubMed ID: 11781225
[TBL] [Abstract][Full Text] [Related]
26. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia.
Doering CB
Methods Mol Biol; 2008; 433():203-12. PubMed ID: 18679625
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of factor VIII in hemophilia.
Lacroix-Desmazes S; Dimitrov JD; Repesse Y
N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
[No Abstract] [Full Text] [Related]
28. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
[TBL] [Abstract][Full Text] [Related]
29. Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
Abildgaard CF
Semin Hematol; 1991 Apr; 28(2 Suppl 1):44. PubMed ID: 1908127
[No Abstract] [Full Text] [Related]
30. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
Franchini M; Lippi G
Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
[TBL] [Abstract][Full Text] [Related]
31. [Gene therapy for hemophilia].
Mimuro J; Sakata Y
Nihon Rinsho; 2005 Dec; 63 Suppl 12():646-54. PubMed ID: 16416868
[No Abstract] [Full Text] [Related]
32. AAV-mediated gene therapy for hemophilia.
Couto LB; Pierce GF
Curr Opin Mol Ther; 2003 Oct; 5(5):517-23. PubMed ID: 14601521
[TBL] [Abstract][Full Text] [Related]
33. Gene-based approaches to the treatment of hemophilia.
High K
Ann N Y Acad Sci; 2002 Jun; 961():63-4. PubMed ID: 12081866
[No Abstract] [Full Text] [Related]
34. Gene therapies for hemophilia hit the mark in clinical trials.
Pickar AK; Gersbach CA
Nat Med; 2018 Feb; 24(2):121-122. PubMed ID: 29414930
[No Abstract] [Full Text] [Related]
35. Gene therapy: Genie in a vector.
Gould J
Nature; 2014 Nov; 515(7528):S160-1. PubMed ID: 25427205
[No Abstract] [Full Text] [Related]
36. Hemophilia clinical gene therapy: brief review.
Walsh CE; Batt KM
Transl Res; 2013 Apr; 161(4):307-12. PubMed ID: 23352600
[TBL] [Abstract][Full Text] [Related]
37. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.
Ye P; Thompson AR; Sarkar R; Shen Z; Lillicrap DP; Kaufman RJ; Ochs HD; Rawlings DJ; Miao CH
Mol Ther; 2004 Jul; 10(1):117-26. PubMed ID: 15233948
[TBL] [Abstract][Full Text] [Related]
38. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.
Chuah MK; VandenDriessche T; Morgan RA
Hum Gene Ther; 1995 Nov; 6(11):1363-77. PubMed ID: 8573610
[TBL] [Abstract][Full Text] [Related]
39. The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A.
Arruda VR
Haematologica; 2015 Jul; 100(7):849-50. PubMed ID: 26130509
[No Abstract] [Full Text] [Related]
40. Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.
Chiang GG; Rubin HL; Cherington V; Wang T; Sobolewski J; McGrath CA; Gaffney A; Emami S; Sarver N; Levine PH; Greenberger JS; Hurwitz DR
Hum Gene Ther; 1999 Jan; 10(1):61-76. PubMed ID: 10022531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
